Literature DB >> 28401184

Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer.

Preston D Crowell1, Andrew S Goldstein2.   

Abstract

While chronic inflammation has been causally associated with several epithelial malignancies, whether it causally contributes to the development of prostate cancer has remained unclear. We recently reported that progenitor-like inflammation-associated luminal cells marked by low expression of Cluster of Differentiation 38 (CD38) can initiate human prostate cancer and predict poor outcome.

Entities:  

Keywords:  CD38; Luminal; Prostate cancer; stem cell

Year:  2017        PMID： 28401184      PMCID： PMC5383352          DOI： 10.1080/23723556.2017.1279723

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  NF-κB gene signature predicts prostate cancer progression.

Authors:  Renjie Jin; Yajun Yi; Fiona E Yull; Timothy S Blackwell; Peter E Clark; Tatsuki Koyama; Joseph A Smith; Robert J Matusik
Journal:  Cancer Res       Date:  2014-03-31       Impact factor: 12.701

2.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38.

Authors:  M Howard; J C Grimaldi; J F Bazan; F E Lund; L Santos-Argumedo; R M Parkhouse; T F Walseth; H C Lee
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

4.  Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin.

Authors:  Oh-Joon Kwon; Li Zhang; Michael M Ittmann; Li Xin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

5.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

6.  Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Authors:  Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Howard L Parnes; Ashraful Hoque; Scott M Lippman; Siobhan Sutcliffe; Sarah B Peskoe; Charles G Drake; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-18       Impact factor: 4.254

7.  Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.

Authors:  Jung Wook Park; John K Lee; John W Phillips; Patrick Huang; Donghui Cheng; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

8.  Identification of a cell of origin for human prostate cancer.

Authors:  Andrew S Goldstein; Jiaoti Huang; Changyong Guo; Isla P Garraway; Owen N Witte
Journal:  Science       Date:  2010-07-30       Impact factor: 47.728

9.  Characterization of autoimmune inflammation induced prostate stem cell expansion.

Authors:  Hsing-Hui Wang; Liang Wang; Travis J Jerde; Bin-Da Chan; Cagri A Savran; Grant N Burcham; Scott Crist; Timothy L Ratliff
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

10.  Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.

Authors:  Xian Liu; Tristan R Grogan; Haley Hieronymus; Takao Hashimoto; Jack Mottahedeh; Donghui Cheng; Lijun Zhang; Kevin Huang; Tanya Stoyanova; Jung Wook Park; Ruzanna O Shkhyan; Behdokht Nowroozizadeh; Matthew B Rettig; Charles L Sawyers; David Elashoff; Steve Horvath; Jiaoti Huang; Owen N Witte; Andrew S Goldstein
Journal:  Cell Rep       Date:  2016-12-06       Impact factor: 9.423
  10 in total
  7 in total

1.  Mass cytometry reveals species-specific differences and a new level of complexity for immune cells in the prostate.

Authors:  Jonathan J Fox; Héctor I Navarro; Takao Hashimoto; Alejandro J Garcia; Andrew S Goldstein
Journal:  Am J Clin Exp Urol       Date:  2019-08-15

Review 2.  Bispecific Antibodies in Multiple Myeloma: Present and Future.

Authors:  Guido Lancman; Dahniel L Sastow; Hearn J Cho; Sundar Jagannath; Deepu Madduri; Samir S Parekh; Shambavi Richard; Joshua Richter; Larysa Sanchez; Ajai Chari
Journal:  Blood Cancer Discov       Date:  2021-08-17

3.  ZNF24 is upregulated in prostate cancer and facilitates the epithelial-to-mesenchymal transition through the regulation of Twist1.

Authors:  Xiangjiang Huang; Nanxin Liu; Xing Xiong
Journal:  Oncol Lett       Date:  2020-03-11       Impact factor: 2.967

Review 4.  Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.

Authors:  Hao-Tian Wu; Xiang-Yu Zhao
Journal:  Int J Biol Sci       Date:  2022-02-21       Impact factor: 6.580

5.  The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.

Authors:  Daisuke Ogiya; Jiye Liu; Hiroto Ohguchi; Keiji Kurata; Mehmet K Samur; Yu-Tzu Tai; Sophia Adamia; Kiyoshi Ando; Teru Hideshima; Kenneth C Anderson
Journal:  Blood       Date:  2020-11-12       Impact factor: 25.476

Review 6.  Natriuretic Peptides: The Case of Prostate Cancer.

Authors:  Letizia Mezzasoma; Matthew J Peirce; Alba Minelli; Ilaria Bellezza
Journal:  Molecules       Date:  2017-10-10       Impact factor: 4.411

7.  GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1.

Authors:  Guangfeng Shao; Yuqiang Liu; Tianjia Ma; Lei Zhang; Mingzhen Yuan; Shengtian Zhao
Journal:  Biosci Rep       Date:  2018-11-30       Impact factor: 3.840
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.